Black I B, Bohn M C, Jonakait G M, Kessler J A
Ciba Found Symp. 1981;83:177-93. doi: 10.1002/9780470720653.ch9.
The initial appearance and development of noradrenergic and adrenergic phenotypic characters was studied in the rat embryo by immunocytochemical methods. Tyrosine hydroxylase and dopamine-beta-hydroxylase (noradrenergic enzymes) appeared at 11.5 days of gestation (Day E 11.5; 27-30 somites) in sympathetic ganglion primordia and in cells of the gut. While tyrosine hydroxylase and dopamine beta-hydroxylase immunoreactivity increased progressively in ganglion primordia, the enzymes disappeared in the gut cells after E 13.5. However, the gut cells themselves persisted, as indicated by the high-affinity uptake of noradrenaline (norepinephrine). Consequently, initial appearance of noradrenergic characters does not ensure persistence and subsequent development, indicating that early phenotypic expression is a mutable process. This contention was supported by the observations that pharmacological stress of pregnant rats in the form of reserpine, or treatment with glucocorticoids, prolonged the appearance of catecholamines in the gut cells. Thus, maternal-embryonic relations in general, and maternal glucocorticoids in particular, may influence embryonic phenotypic expression. Treatment of embryos with nerve growth factor also prolonged the appearance of noradrenergic characters in the gut cells. Expression of the adrenergic phenotype was apparently regulated differently from noradrenergic expression, since phenylethanolamine-N-methyltransferase (PNMT), the adrenaline-(epinephrine)-synthesizing enzyme, was undetectable in ganglion primordia and gut cells. PNMT initially appeared at E 17.5 in cells which had migrated to be adrenal anlage. Extensive studies suggest that the initial appearance of PNMT occurs independently of glucocorticoid regulation, while subsequent development is dependent on corticoids.
采用免疫细胞化学方法,对大鼠胚胎中去甲肾上腺素能和肾上腺素能表型特征的最初出现和发育进行了研究。酪氨酸羟化酶和多巴胺-β-羟化酶(去甲肾上腺素能酶)在妊娠11.5天(胚胎第11.5天;27 - 30体节)时出现在交感神经节原基和肠道细胞中。虽然酪氨酸羟化酶和多巴胺-β-羟化酶的免疫反应性在神经节原基中逐渐增加,但这些酶在胚胎第13.5天后在肠道细胞中消失。然而,如去甲肾上腺素(norepinephrine)的高亲和力摄取所示,肠道细胞本身持续存在。因此,去甲肾上腺素能特征的最初出现并不能确保其持续存在和后续发育,这表明早期表型表达是一个可变的过程。这一观点得到了以下观察结果的支持:以利血平形式对怀孕大鼠进行药理应激,或用糖皮质激素治疗,会延长肠道细胞中儿茶酚胺的出现时间。因此,一般的母胎关系,特别是母体糖皮质激素,可能会影响胚胎的表型表达。用神经生长因子处理胚胎也会延长肠道细胞中去甲肾上腺素能特征的出现时间。肾上腺素能表型的表达显然与去甲肾上腺素能表达的调节方式不同,因为在神经节原基和肠道细胞中未检测到肾上腺素(epinephrine)合成酶苯乙醇胺 - N - 甲基转移酶(PNMT)。PNMT最初在胚胎第17.5天出现在迁移到肾上腺原基的细胞中。广泛的研究表明,PNMT的最初出现独立于糖皮质激素调节,而其后续发育则依赖于皮质类固醇。